Merck’s KEYTRUDA® Plus Chemotherapy Met Primary Endpoint of Progression-Free Survival as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma

KEYTRUDA® plus chemotherapy significantly improved progression-free survival versus standard of care chemotherapy alone, as first-line treatment for patients with stage III-IV or recurrent endometrial carcinoma, regardless of mismatch repair status